Lein Applied Diagnostics Ltd, a Berkshire-based company, is developing a revolutionary new product to measure blood glucose levels diabetics. It has successfully completed clinical tests of its advanced prototypes and secured further investment from Seven Spires Investments, a member of Thames Valley Investment Network (TVIN).
The funding will enable Lein to accelerate the development programme for its non-invasive optical instrument.
In recent clinical tests, an advanced prototype of the instrument, which uses an innovative optical measurement technique to track the amount of glucose in the eye, produced well correlated readings of blood glucose levels when tested on volunteers with widely varying ages. Successful tests have also been performed on volunteers with contact lenses.
Dr Dan Daly, Director of Lein Applied Diagnostics, explained: “We are delighted with the excellent results from our clinical tests, and pleased that Seven Spires Investments have provided us with further investment, following on from the initial funding secured after we presented at a TVIN meeting. Having achieved our clinical and technical goals, we are now ready to accelerate our development programme.
Source: Innovations Report